Timothy grass allergen-specific Immunoglobulin E (IgE) complex (IgE-Phl p complex)

This target refers to the immunological complex formed by Immunoglobulin E (IgE) antibodies specific to Timothy grass (Phleum pratense) allergens and their interaction with antigen-presenting cells (APCs) via Fc receptors such as CD23 and FcεRI [1][2]. In sensitized individuals, major Timothy grass allergens like Phl p 1 and Phl p 5 bind to IgE on the surface of APCs, facilitating a process known as IgE-facilitated antigen presentation (IgE-FAP) [3]. This mechanism significantly enhances the activation of allergen-specific T cells, driving the allergic cascade and chronic inflammation associated with allergic rhinitis and allergic asthma [4]. Therapeutic interventions targeting this axis include anti-IgE monoclonal antibodies like Omalizumab, which sequester free IgE to prevent its binding to receptors, and allergen-specific immunotherapy (AIT), which aims to induce immune tolerance and promote the production of protective IgG4 antibodies [5][6]. Monitoring this target involves measuring serum levels of Timothy grass-specific IgE and assessing basophil activation in response to allergen challenge [3]. Safety concerns primarily involve the risk of anaphylaxis or systemic allergic reactions during treatment with allergens or potent immunomodulators [6]. Sources: [1] van Neerven et al., 1999, PubMed: 10485873. [2] WHO/IUIS Allergen Nomenclature, Phleum pratense. [3] Shamji et al., 2011, J Allergy Clin Immunol. [4] Durham et al., 2016, Nature Reviews Immunology. [5] FDA Label: Xolair (omalizumab). [6] EMA Summary of Product Characteristics: Grazax.

Other names

Phleum pratense-specific IgEIgE-facilitated antigen presentation complexTimothy grass allergen-IgE-CD23 axisIgE-Phl p complex

Neutralization of free IgE to prevent receptor binding and inhibition of IgE-facilitated antigen presentation; induction of immune tolerance through allergen-specific immunotherapy.